- Home
- HROW vs SVM Comparison
HROW vs SVM Comparison
Compare HROW & SVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- SVM
- Stock Information
- Founded
- HROW 1998
- SVM N/A
- Country
- HROW United States
- SVM Canada
- Employees
- HROW N/A
- SVM N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- SVM Precious Metals
- Sector
- HROW Health Care
- SVM Basic Materials
- Exchange
- HROW Nasdaq
- SVM Nasdaq
- Market Cap
- HROW 1.1B
- SVM 1.1B
- IPO Year
- HROW N/A
- SVM N/A
- Fundamental
- Price
- HROW $33.02
- SVM $4.66
- Analyst Decision
- HROW Strong Buy
- SVM Strong Buy
- Analyst Count
- HROW 7
- SVM 1
- Target Price
- HROW $61.83
- SVM $6.75
- AVG Volume (30 Days)
- HROW 453.8K
- SVM 5.0M
- Earning Date
- HROW 08-11-2025
- SVM 08-07-2025
- Dividend Yield
- HROW N/A
- SVM 0.54%
- EPS Growth
- HROW N/A
- SVM 40.00
- EPS
- HROW N/A
- SVM 0.28
- Revenue
- HROW $212,858,000.00
- SVM $298,895,000.00
- Revenue This Year
- HROW $46.17
- SVM $8.43
- Revenue Next Year
- HROW $39.97
- SVM $27.40
- P/E Ratio
- HROW N/A
- SVM $16.55
- Revenue Growth
- HROW 53.49
- SVM 38.90
- 52 Week Low
- HROW $20.85
- SVM $2.87
- 52 Week High
- HROW $59.23
- SVM $5.32
- Technical
- Relative Strength Index (RSI)
- HROW 48.64
- SVM 52.16
- Support Level
- HROW $30.12
- SVM $4.26
- Resistance Level
- HROW $33.90
- SVM $4.88
- Average True Range (ATR)
- HROW 1.70
- SVM 0.18
- MACD
- HROW -0.50
- SVM -0.04
- Stochastic Oscillator
- HROW 36.39
- SVM 55.65
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About SVM Silvercorp Metals Inc.
Silvercorp Metals Inc is a mineral exploration company, engaged in the acquisition, exploration, development, and mining of mineral properties. The company's producing mines are located in China, and exploration and development projects are located in China and Ecuador. Its project portfolio comprises the El Domo copper-gold and the Condor gold project in Ecuador. In addition, it operates several silver-lead-zinc mines at the Ying Mining District in Henan Province, China, and the GC silver-lead-zinc mine in Guangdong Province, China. A majority of the company's revenue is generated through the sale of silver concentrates. Its reportable operating segments are the Ying Mining District and GC Mine in China, which derive maximum revenue, and the El Domo and Condor projects in Ecuador.